Semaglutide organ outcomes

SELECT

SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. The trial compared semaglutide with placebo and counted cardiovascular death, nonfatal heart attack or nonfatal stroke as a combined outcome. Its hazard ratio was 0.80, with a 95% confidence interval of 0.72–0.90.

A hazard ratio compares event rates over the follow-up period. Here it favoured semaglutide. The finding concerns that cardiovascular outcome in that population; it gives a different answer from the amount of weight lost.

SELECT warrants a prominent place here because serious cardiovascular events were counted. A change in body size can be visible; a difference in serious cardiovascular events requires a trial to become visible at all.

FLOW: kidney disease

FLOW studied 3,533 adults with type 2 diabetes and chronic kidney disease. Its primary combined outcome included kidney failure, a decline of at least 50% in estimated filtration, or kidney-related or cardiovascular death. Semaglutide reduced this outcome versus placebo, with a hazard ratio of 0.76 and a 95% confidence interval of 0.66–0.88.

Those endpoints bring several kinds of deterioration into a single comparison. The kidney and cardiovascular components need to stay attached to the result, just as the participants’ diabetes and kidney disease do. I resist turning SELECT and FLOW into a universal claim of organ protection; the two trials already offer substantial, specific findings.

STEP 1: weight change

STEP 1 randomized 1,961 adults with overweight or obesity who did not have diabetes. Mean body-weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo. These are changes from baseline in the trial groups.

The result is striking. Its anatomical composition still matters: weight includes fat, water and other lean tissue. Losing weight and preserving muscle are related questions with different measurements. This is one reason the tesamorelin results, which separate visceral fat and lean mass, deserve their own discussion rather than a borrowed weight-loss headline.

SURMOUNT-5

In SURMOUNT-5, a head-to-head trial in 751 adults with obesity, mean weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide. The difference was statistically significant.

This is a useful comparison because the treatments met within the same trial. The result addresses weight change under that study’s conditions. Rankings assembled from different trials, populations and outcomes would require much more caution. For me, the direct comparison makes the limits easier to see as well as the difference.

Hunger, digestion and reported effects

Semaglutide mimics GLP-1, the gut hormone involved in appetite and blood-sugar control after meals. It supports insulin release when blood sugar is elevated, suppresses glucagon and slows gastric emptying. Its prolonged action reflects changes to the peptide and binding to albumin, a circulating blood protein. The semaglutide safety review discusses the drug’s pharmacology alongside its adverse effects.

Community accounts often describe quieter “food noise,” reduced cravings, changed tastes or food becoming unappealing. Reports also include reflux, tiredness, headaches, hair shedding and reactions near injection sites. These are anecdotal observations rather than clinical evidence, and they cannot establish how often a change occurs or what caused it. Their language describes an experience of eating that a weight percentage leaves out.

Prescription safety

The safety review identifies nausea, vomiting, diarrhoea and constipation as dominant adverse effects, generally transient and mild to moderate. It also describes increased gallbladder or biliary disease. Pancreatic and thyroid-cancer signals remained uncertain because the relevant events were uncommon; the review also discusses worsening diabetic retinopathy in a high cardiovascular-risk trial population.

These concerns deserve space beside the efficacy results. A clear benefit in a trial leaves individual contraindications, other medicines and tolerability for a prescribing clinician to assess. Buying semaglutide and having it prescribed are different matters to me: not everyone is eligible, and a licensed U.S. clinician decides after an evaluation whether to prescribe it through Promise Peptides (mypromise.com). Compounded semaglutide is not FDA-approved.

Approved semaglutide products have specific prescription uses and warnings. Their clinical evidence applies to the tested medicines and conditions; it does not establish equivalent safety or effects for unchecked copies. This collection offers no instructions for taking semaglutide.